Switch theme
Sign up to access all valuation multiples
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
1999
1.3K+
LTM Revenue $406M
LTM EBITDA -$910M
$12.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Insmed has a last 12-month revenue (LTM) of $406M and a last 12-month EBITDA of -$910M.
In the most recent fiscal year, Insmed achieved revenue of $364M and an EBITDA of -$819M.
Insmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Insmed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $406M | XXX | $364M | XXX | XXX | XXX |
| Gross Profit | $313M | XXX | $278M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | -$910M | XXX | -$819M | XXX | XXX | XXX |
| EBITDA Margin | -224% | XXX | -225% | XXX | XXX | XXX |
| EBIT | -$911M | XXX | -$787M | XXX | XXX | XXX |
| EBIT Margin | -224% | XXX | -216% | XXX | XXX | XXX |
| Net Profit | -$950M | XXX | -$914M | XXX | XXX | XXX |
| Net Margin | -234% | XXX | -251% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $548M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Insmed's stock price is $70.
Insmed has current market cap of $12.7B, and EV of $12.6B.
See Insmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12.6B | $12.7B | XXX | XXX | XXX | XXX | $-5.43 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Insmed has market cap of $12.7B and EV of $12.6B.
Insmed's trades at 34.8x EV/Revenue multiple, and -15.4x EV/EBITDA.
Equity research analysts estimate Insmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Insmed has a P/E ratio of -13.4x.
See valuation multiples for Insmed and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.7B | XXX | $12.7B | XXX | XXX | XXX |
| EV (current) | $12.6B | XXX | $12.6B | XXX | XXX | XXX |
| EV/Revenue | 31.1x | XXX | 34.8x | XXX | XXX | XXX |
| EV/EBITDA | -13.9x | XXX | -15.4x | XXX | XXX | XXX |
| EV/EBIT | -13.9x | XXX | -16.1x | XXX | XXX | XXX |
| EV/Gross Profit | 40.4x | XXX | n/a | XXX | XXX | XXX |
| P/E | -13.4x | XXX | -13.9x | XXX | XXX | XXX |
| EV/FCF | -15.7x | XXX | -17.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInsmed's last 12 month revenue growth is 68%
Insmed's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.8M for the same period.
Insmed's rule of 40 is -148% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Insmed's rule of X is -54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Insmed and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 68% | XXX | 65% | XXX | XXX | XXX |
| EBITDA Margin | -224% | XXX | -225% | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -148% | XXX | -157% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 165% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 293% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Insmed acquired XXX companies to date.
Last acquisition by Insmed was XXXXXXXX, XXXXX XXXXX XXXXXX . Insmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Insmed founded? | Insmed was founded in 1999. |
| Where is Insmed headquartered? | Insmed is headquartered in United States of America. |
| How many employees does Insmed have? | As of today, Insmed has 1.3K+ employees. |
| Who is the CEO of Insmed? | Insmed's CEO is Mr. William H. Lewis, J.D.,M.B.A.. |
| Is Insmed publicy listed? | Yes, Insmed is a public company listed on NAS. |
| What is the stock symbol of Insmed? | Insmed trades under INSM ticker. |
| When did Insmed go public? | Insmed went public in 2000. |
| Who are competitors of Insmed? | Similar companies to Insmed include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Insmed? | Insmed's current market cap is $12.7B |
| What is the current revenue of Insmed? | Insmed's last 12 months revenue is $406M. |
| What is the current revenue growth of Insmed? | Insmed revenue growth (NTM/LTM) is 68%. |
| What is the current EV/Revenue multiple of Insmed? | Current revenue multiple of Insmed is 31.1x. |
| Is Insmed profitable? | Yes, Insmed is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Insmed? | Insmed's last 12 months EBITDA is -$910M. |
| What is Insmed's EBITDA margin? | Insmed's last 12 months EBITDA margin is -224%. |
| What is the current EV/EBITDA multiple of Insmed? | Current EBITDA multiple of Insmed is -13.9x. |
| What is the current FCF of Insmed? | Insmed's last 12 months FCF is -$808M. |
| What is Insmed's FCF margin? | Insmed's last 12 months FCF margin is -199%. |
| What is the current EV/FCF multiple of Insmed? | Current FCF multiple of Insmed is -15.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
